ELPA president Marko_Korenjak has been elected as member of the Impact Board of the medical research project Decision.

This project, of which ELPA is part, is focused on the end-stage chronic liver disease (cirrhosis) that is a major cause of morbidity and mortality, and has a large socioeconomic impact because of high health care costs and the patients’ inability to work or seek employment.

The presence of ELPA in the Impact Board is a great news because it represents a step further to strengthen patients’ participation in medical research projects. Being part of them enriches the research field with the unique views of patients’ organizations and ELPA, with its exclusive way in communicating and disseminating scientific results, acts like a translator making complex contents accessible to its members and to a broader public.

ELPA part of 21 European institutions who join the  forces to tackle end-stage #liverdisease and #ACLF with a #systemsmedicine approach. Under the aegis of ef clif with support from EASL and ELPA, DECISION aims to develop new treatments and tests for prediction and treatment response.

EU Project Partners

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.